FEC

DRUG3 trials

Sponsors

Hoffmann-La Roche, University of Chicago

Conditions

Breast CancerBreast Cancer FemaleBreast Cancer Stage IIBreast Cancer Stage IIIHER2-positive Breast Cancer

Phase 2

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

CompletedNCT00976989

Hoffmann-La RocheBreast Cancer

Start: 2009-11-30End: 2016-01-31Updated: 2017-02-06

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

WithdrawnNCT03058939

University of ChicagoBreast Cancer, Breast Cancer Stage II, Breast Cancer Stage III

Start: 2018-11-30End: 2019-06-30Updated: 2019-04-22

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Active, not recruitingNCT03879577

University of ChicagoBreast Cancer, Breast Cancer Female, Breast Cancer Stage II +2

Start: 2019-11-25End: 2026-09-30Updated: 2026-01-21

Related Papers

The difference of clinical and molecular characteristics between HR-positive/HER2-positive and HR-negative/HER2-positive early breast cancer: A secondary analysis of 11 clinical trials.

Journal of Clinical Oncology2025-05-28

Abstract OT2-21-01: Assessing Response to neoadjuvant Taxotere and TrAstuzumab in Nigerian women with HER2-positive breast cancer (ARETTA)

Cancer Research2023-03-01

Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.

2022-10-074 citations

Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA).

Journal of Clinical Oncology2022-06-01

ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol

JCO Global Oncology2020-07-067 citations

Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis

Cancer Research2020-02-154 citations

Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.

2019-04-119 citations

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.

2017-12-08183 citations

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

2017-04-0126 citations

Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

Cancer Research2017-02-153 citations

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study.

2014-07-0862 citations